This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-23 and is reviewed periodically as new material appears.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Internal Chinese government documents leaked to the press in November 2019 showed that Xi personally ordered a security crackdown in Xinjiang, saying that the party must show "absolutely no mercy" and that officials use all the "weapons of the people's democratic dictatorship" to suppress those "infected with the virus of extremism." The papers also showed that Xi repeatedly discussed Islamic extremism in his speeches, likening it to a "virus" or a "drug" that could be only addressed by "a period of painful, interventionary treatment." However, he also warned against the discrimination against Uyghurs and rejected proposals to eradicate Islam in China, calling that kind of viewpoint "biased, even wrong." Xi's exact role in the building of internment camps has not been publicly reported, though he's widely believed to be behind them and his words have been the source for major justifications in the crackdown in Xinjiang. China began to wind down the camps in 2019, and some detainees were transferred to the penal system, while others were transferred to forced labor and factory work programs. In a July 2022 visit to Xinjiang, Xi urged local officials to always listen to the citizens' voices and to improve efforts in preserving ethnic minority culture. In a visit to Xinjiang the following year, Xi stated that the region was "no longer a remote area" and should open up more for tourism to attract domestic and foreign visitors.
to be undetectable using standard 1970s and 1980s NATO chemical detection equipment; to defeat NATO chemical protective gear; to be safer to handle; and to circumvent the Chemical Weapons Convention list of controlled precursors, classes of chemical and physical form. Some of these agents are binary weapons, in which precursors for the nerve agents are mixed in a munition to produce the agent just prior to its use. The precursors are generally significantly less hazardous than the agents themselves, so this technique makes handling and transporting the munitions a great deal simpler. Additionally, precursors to the agents are usually much easier to stabilise than the agents themselves, so this technique also makes it possible to increase the shelf life of the agents. This has the disadvantage that careless preparation may produce a non-optimal agent. During the 1980s and 1990s, binary versions of several Soviet agents were developed and are designated as "Novichok" agents.
BRD-6929, also widely known as "compound 60" (Cpd-60 or Cmpd60), is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It has been described in the past as the prototypical selective HDAC1 and HDAC2 inhibitor. However, subsequent findings suggest that BRD-6929 may not actually be selective for HDAC1 and HDAC2 over HDAC3.
Sources: en.wikipedia.org
Allergen immunotherapy is useful for environmental allergies, allergies to insect bites, and asthma. Its benefit for food allergies is unclear and thus not recommended. Immunotherapy involves exposing people to larger and larger amounts of allergen in an effort to change the immune system's response. Meta-analyses have found that injections of allergens under the skin is effective in the treatment in allergic rhinitis in children and in asthma. The benefits may last for years after treatment is stopped. It is generally safe and effective for allergic rhinitis and conjunctivitis, allergic forms of asthma, and stinging insects. To a lesser extent, the evidence also supports the use of sublingual immunotherapy for rhinitis and asthma. For seasonal allergies the benefit is small. In this form the allergen is given under the tongue and people often prefer it to injections. Immunotherapy is not recommended as a stand-alone treatment for asthma.
Nucleonica nuclear science portal Nucleonica's Decay Engine for professional online decay calculations EPA – Radioactive Decay Government website listing isotopes and decay energies National Nuclear Data Center – freely available databases that can be used to check or construct decay chains IAEA – Live Chart of Nuclides (with decay chains) Decay Chain Finder
The mean is T and the variance is zero. The RTD of a real reactor deviates from that of an ideal reactor, depending on the hydrodynamics within the vessel. A non-zero variance indicates that there is some dispersion along the path of the fluid, which may be attributed to turbulence, a non-uniform velocity profile, or diffusion. If the mean of the distribution is earlier than the expected time T it indicates that there is stagnant fluid within the vessel. If the RTD curve shows more than one main peak it may indicate channeling, parallel paths to the exit, or strong internal circulation. In PFRs, reactants enter the reactor at one end and react as they move down the reactor. Consequently, the reaction rate is dependent on the concentrations which vary along the reactor requiring the inverse of the reaction rate to be integrated over the fractional conversion.
Emma Barnett (born 5 February 1985); broadcaster and journalist for The Jewish Chronicle; main presenter of Woman's Hour on BBC Radio 4 since January 2021, and subsequently for the BBC Radio Four Today programme. Mir Basri, (Arabic: مير بصري; 1911-2006) was an Iraqi writer, economist, journalist, politician and poet. Among many public positions he held, Basri served as the head and central leader of Iraqi and Baghdad's Jewish community; joined the Iraqi Foreign Ministry, going on to hold a number of government positions including many relating to Iraq's Jewish community. He held many positions in Iraq, including: secretary of the advisory committee and supervisor of supply affairs, director general and secretary at the Iraqi Ministry of Foreign Affairs, undersecretary and director of protocol therein, and president of the Baghdad Chamber of Commerce. He also attended many international conferences representing Iraq. Basri also held the position of honorary president of the Jewish Community in Iraq during the late sixties and early seventies, and was economics columnist for the newspapers Al-Ikhwa Al-Watani, Al-Bilad, and Al-Shaab, and edited the weekly newspaper Al-Daleel. Rachel Beer, editor-in-chief of The Observer and The Sunday Times, born in Bombay to Sassoon David Sassoon, of the Iraqi Sassoon family. Rafael Behr (born June 1974), of South African Jewish ancestry; columnist at The Guardian, Financial Times; Jewish Chronicle; former political editor of the New Statesman.
Sources: en.wikipedia.org
Gaston Bazille then proposed grafting traditional French vines onto American rootstock.) However, importation of American vines did not entirely solve the problem: some American grape varieties struggled in France's chalky soils and succumbed to Phylloxera. By trial and error, American vines were found that could tolerate chalky soils. Meanwhile, entomologists worked to unravel the strange life cycle of Phylloxera, a project that was completed in 1874.
If areas were depopulated of Neanderthals as a consequence of climate change (specifically Heinrich event 4) or a natural disaster (the Campanian Ignimbrite eruption), Neanderthals may not have been as fast as modern humans in recolonising.
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.